MedTrace Logo

Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

NCT05964647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-17

No results posted yet for this study

Summary

The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone

Conditions

  • Healthy

Interventions

DRUG

LSD (150 µg) + ketanserin (40 mg)

Drug: LSD (150 µg) per os, single dose Other: Ketanserin (40 mg) per os, single dose

DRUG

LSD (150 µg) + olanzapine (10 mg)

Drug: LSD (150 µg) per os, single dose Other: Olanzapine (10 mg) per os, single dose

DRUG

LSD (150 µg) + lorazepam (2 mg)

Drug: LSD (150 µg) per os, single dose Other: Lorazepam (2 mg) per os, single dose

DRUG

LSD (150 µg) + placebo

Drug: LSD (150 µg) per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

DRUG

Placebo + placebo

Drug: Placebo (Capsules containing mannitol looking identical to the other drugs) Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05964647 on ClinicalTrials.gov